| 000 | 01460 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515235219.0 | ||
| 264 | 0 | _c20110111 | |
| 008 | 201101s 0 0 eng d | ||
| 022 | _a1744-7682 | ||
| 024 | 7 |
_a10.1517/14712598.2010.514901 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWéclawiak, Hugo | |
| 245 | 0 | 0 |
_aBiological agents in kidney transplantation: belatacept is entering the field. _h[electronic resource] |
| 260 |
_bExpert opinion on biological therapy _cOct 2010 |
||
| 300 |
_a1501-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAbatacept |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCalcineurin Inhibitors |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aGraft Rejection _ximmunology |
| 650 | 0 | 4 |
_aGraft Survival _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xadverse effects |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aKidney Transplantation _ximmunology |
| 650 | 0 | 4 |
_aSirolimus _xtherapeutic use |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKamar, Nassim | |
| 700 | 1 | _aOuld-Mohamed, Abdoulattif | |
| 700 | 1 | _aCardeau-Desangles, Isabelle | |
| 700 | 1 | _aRostaing, Lionel | |
| 773 | 0 |
_tExpert opinion on biological therapy _gvol. 10 _gno. 10 _gp. 1501-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14712598.2010.514901 _zAvailable from publisher's website |
| 999 |
_c20062255 _d20062255 |
||